Prospects and challenges of building a cancer vaccine targeting telomerase

Por Vonderheide, Robert H.
Publicado em 2007

Tumor-promoting inflammatory networks in pancreatic neoplasia: Another reason to loatheKras

Por Vonderheide, Robert H.
Publicado em 2014

Anti-CD40 agonist antibodies: preclinical and clinical experience

Por Khalil, Magi, Vonderheide, Robert H.
Publicado em 2007

CD40 therapy and surgery: a potential immunological partnership

Por Byrne, Katelyn T., Vonderheide, Robert H.
Publicado em 2013

CD40 stimulation obviates innate sensors and drives T cell immunity in cancer

Por Byrne, Katelyn T., Vonderheide, Robert H.
Publicado no Cell Rep (2016)

Telomerase as a tumor-associated antigen for cancer immunotherapy

Por Patel, Kunal P., Vonderheide, Robert H.
Publicado em 2004

Agonistic CD40 antibodies and cancer therapy

Por Vonderheide, Robert H., Glennie, Martin J.
Publicado em 2013

Inflammatory networks and immune surveillance of pancreatic carcinoma

Por Vonderheide, Robert H., Bayne, Lauren J.
Publicado em 2013

Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer

Por Richman, Lee P., Vonderheide, Robert H.
Publicado em 2013

Dynamic interplay of oncogenes and T cells impacts induction of PD-1 expression in the tumor microenvironment

Por Rech, Andrew J., Vonderheide, Robert H.
Publicado em 2013

Engineering T cells for cancer: our synthetic future

Por Vonderheide, Robert H, June, Carl H
Publicado em 2014

Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking

Por Richman, Lee P, Vonderheide, Robert H
Publicado em 2014

CXCR2-dependent accumulation of tumor-associated neutrophils regulates T-cell immunity in pancreatic ductal adenocarcinoma

Por Chao, Timothy, Furth, Emma E., Vonderheide, Robert H.
Publicado no Cancer Immunol Res (2016)

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation

Por Carpenter, Erica L, Mick, Rosemarie, Rüter, Jens, Vonderheide, Robert H
Publicado em 2009

Special Conference on Tumor Immunology and Immunotherapy: A New Chapter

Por Byrne, Katelyn T., Vonderheide, Robert H., Jaffee, Elizabeth M., Armstrong, Todd D.
Publicado no Cancer Immunol Res (2015)

CSF-1R–dependent lethal hepatotoxicity when agonistic CD40 antibody given before but not after chemotherapy

Por Byrne, Katelyn T., Leisenring, Nathan H., Bajor, David L., Vonderheide, Robert H.
Publicado no J Immunol (2016)

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors

Por Rüter, Jens, Antonia, Scott J, Burris, Howard A, Huhn, Richard D, Vonderheide, Robert H
Publicado em 2010

Tissue regenerative delays and synthetic lethality in adult mice upon combined deletion of ATR and p53

Por Ruzankina, Yaroslava, Schoppy, David W., Asare, Amma, Clark, Carolyn E., Vonderheide, Robert H., Brown, Eric J.
Publicado em 2009

Mammary Carcinoma Cell Derived Cyclooxygenase 2 Suppresses Tumor Immune Surveillance by Enhancing Intratumoral Immune Checkpoint Activity

Por Markosyan, Nune, Chen, Edward P, Evans, Rebecca A, Ndong, Victoire, Vonderheide, Robert H, Smyth, Emer M
Publicado em 2013

Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients

Por Ganetsky, Alex, Miano, Todd A., Hughes, Mitchell E., Vonderheide, Robert H., Porter, David L., Reshef, Ran
Publicado no J Antimicrob Chemother (2015)